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Disruption of NUBPL due to balanced translocation [t(3;14)
(q26.33;q14)] increases severity of a family-specific PGK1 mutation
D. David1, I. Haltrich2, B. Marques1, C. Fernandes1, S. Malveiro1, G. Fekete2;  
1Department of Human Genetics, National Institute of Health Dr Ricardo Jorge, Lisboa, 
Portugal, 22nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.An intriguing group of familiar translocations are those which not always segregate with the “associated” disorder. Here we report the genetic altera-tions underlying a clinical phenotype characterized by haemolytic anemia and neuro-myopathy, seemingly associated with the familial translocation 
[t(3;14)(3q26.33;q14)]. Two affected probands and two unaffected relati-
ves have been identified as carriers. The 3q26.33 breakpoint was mapped about 40 kb from the TTC14 5’ end, at position 180.28 Mb and the 14q14 
breakpoint within IVS 6 of NUBPL. The latter has been implicated in the ae-
tiology of mitochondrial complex I deficiency (OMIM 252010). The most im-
portant additional possible candidate gene identified in this region is DNA-
JC19 causing an autosomal recessive disorder (OMIN 610198) that partially overlaps the reported phenotype. The recognition that a deceased relative most likely suffered from a similar disorder suggested the possibility of an X-linked disorder. Exclusion of additional genomic alterations within the breakpoint regions or elsewhere in the genome, familial X-chromosome se-
gregation analysis and whole exome sequencing identified a novel missen-se mutation, c.358G>A, p.Glu120Lys, in exon 4 of phosphoglycerate kinase 1 (PGK1). Segregation analysis confirmed the association of this mutation with the disease phenotype. Re-evaluation of clinical data indicates that 
myopathy is considerably more severe in PGK1 deficient patients carriers of 
the translocation. The confirmation of this observation is currently under-
way. In conclusion, we have identified a novel PGK1 mutation whose clinical phenotype is exacerbated by co-inheritance of the disrupted NUBPL and/or by alterations affecting the genes in the breakpoint regions.
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Novel mutations in HPD causing tyrosinemia type III in Northern 
Israel
T. C. Falik-Zaccai1,2, D. Raviv Shay1, N. Nasser Samra1, L. Kalfon1, O. Dementyev1, M. 
Baydany1, F. Fares3, A. Shaag4, S. Almashanu5, H. Mandel6,7;  
1Western Galilee Hospital-Naharia, Naharia, Israel, 2The Galilee Faculty of Medicine, 
Bar Ilan University, Safed, Israel, 3Department of Human Biology, Faculty of Natural 
Sciences, University of Haifa, Mount Carmel, Haifa, Israel, 4Monique and Jacques 
Roboh Department of Genetic Research, Hadassah, Hebrew University Medical Center, 
Jerusalem, Israel, 5Newborn Screening, National Center for Newborn Screening, Tel-
Hashomer Hospital, Tel Aviv, Israel, 6Meyer Children’s Hospital, Metabolic Unit, Rambam 
Medical Center, Haifa, Israel, 7Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Impaired tyrosine catabolism result in elevated plasma tyrosine concen-trations. Malfunction enzymes along the tyrosine catabolic pathway results 
in hereditary tyrosinemia. Tyrosinemia type III is caused by deficiency in 4-HPPD. To date, only 14 cases have been described, showing a wide clinical spectrum. Reported patients have either presented with mental retardation and neurological symptoms while others, detected by neonatal screening, have been asymptomatic.We report 4 new patients, 3 from a highly consanguineous Druze family, pre-senting elevated blood tyrosine levels with normal development and intel-ligence. Clinical evaluation revealed novel eye and skin phenotype not pre-
viously described in tyrosinemia type III. The fourth patient, from a Muslim origin consanguineous family, was diagnosed with hypertyrosinemia in the neonatal metabolic screen. Her psychomotoric development is normal for her age. Sequencing revealed two novel splicing mutations in HPD. Healthy control screening from two Druze villages detected 3:100 carriers in one village and none in the second.
We suspect tyrosinemia type III to be under-diagnosed and more common than is currently known. With neonatal metabolic screen becoming more widespread, more patients are likely to be diagnosed. Molecular analysis 
is the gold standard for diagnosing tyrosinemia type II and III. In light of 
the minute number of patients with tyrosinemia type III worldwide, clinical 
characterization of new patients is highly significant, determining the natu-ral history of the disease, and describing the treatment and its contribution to normal growth and development of the patients.
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A homozygous UQCRC2 mutation cause a neonatal onset metabolic 
decompensation due to complex III deficiency.
N. Miyake1, S. Yano2, Y. Goto3, N. Matsumoto1;  
1Department of Human Genetics, Yokohama City University Graduate School of Medicine, 
Yokohama, Japan, 2Genetics Division, Department of Pediatrics, LAC+USC Medical Center, 
Keck School of Medicine, University of Southern California, Los Angeles, CA, United 
States, 3Department of Mental Retardation and Birth Defect Research, National Institute 
of Neuroscience, NCNP, Tokyo, Japan.The mitochondrial respiratory chain generates energy as adenosine tri-phosphate (ATP) by means of the electron-transport chain and the oxida-tive-phosphorylation system. The mitochondrial respiratory chain, located 
in the inner mitochondrial membrane, is composed of five complexes: I, II, 
III, IV, and V. Among them, mitochondrial complex III (CIII) comprises 11 subunits encoded by one mitochondrial and 10 nuclear genes. Until now, 
mutations in four genes have been known to cause autosomal recessive CIII 
deficiencies: UQCRB, UQCRQ, BCS1L and TTC19. UQCRB and UQCRQ encode 
components of CIII itself, while BCS1L and TTC19 produce mitochondrial assembly factors. Here, we report three patients from a consanguineous Me-xican family presenting with neonatal onset of hypoglycemia, lactic acidosis, ketosis, and hyperammonemia. By whole exome sequencing combined with linkage analysis, we successfully found a homozygous missense mutation in UQCRC2 that encodes mitochondrial ubiquinol-cytochrome c reductase 
core protein II. In its native state, the CIII monomer is quickly converted into a catalytically active homodimer that is incorporated into a supercomplex, and this supercomplex functions as a single enzyme. Based on structural modeling, the mutation (p.Arg183Trp) was predicted to destabilize the hy-
drophobic core at the subunit interface of the core protein II homodimer. In 
vitro studies using fibroblasts from the index patient clearly indicated CIII 
deficiency, as well as impaired assembly of the supercomplex consisting of 
complexes I, III, and IV. This is the first described human disease caused by 
UQCRC2 abnormality.
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Association and molecular analysis of 3’ UTR polymorphisms of the 
WFS1 gene
Z. Ronai, N. Nemeth, A. Somogyi, M. Sasvari-Szekely;  
Semmelweis University, Budapest, Hungary.Wolframin is a major protein of the endoplasmic reticulum, loss of function mutations of the WFS1 gene result in the monogenic Wolfram-syndrome, characterized by optic atrophy, diabetes insipidus, diabetes mellitus and deafness, whereas polymorphisms of the gene are putative risk factors of diabetes. Our aim was the association and molecular analysis of two SNPs 
(rs1046322 and rs9457) in the 3’ UTR of the WFS1 gene, which are sup-posed to alter the miRNA binding according to in silico data.Association analysis was carried out by case-control study. 617 patients and 1147 healthy controls particiapted. Genotype analysis was carried out using PCR based methods, functional analysis was done by luciferase reporter sy-stem.
Our results showed that rs9457 “C” allele was significantly more frequent among patients with type 2 diabetes, whereas the rs1046322 variant sho-
wed a significant association with the type 1 form of the disease. Luciferase 
reporter experiments suggested that the rs1046322 and the rs9457 SNPs altered the binding of miRNA-668 and miRNA-185, respectively.
Our results suggest that the rs9457 and rs1046322 polymorphisms are the genetic components of diabetes mellitus. Earlier studies showed an associa-tion between WFS1 rs1046320 and diabetes, however no biological func-tion of the SNP could be observed. We suggest that this result is due to the 
strong linkage disequilibrium between rs9457 and rs1046320, thus the lat-
ter polymorphism can be a genetic marker of rs9457.This work was supported by the Hungarian grant OTKA K83766 and by the 
Bolyai János Scholarship (BO/00089/10/5) of the Hungarian Academy of Sciences.
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